

**The 22nd Japan-Korea Joint Symposium on
Helicobacter infection
Program**

**Japan-Korea Joint Symposium 1-3
Presentations by YIA (Young Investigator Award)
Poster session**

Japan-Korea Joint Symposium 1

July 4(Sat.)13:40~14:10 Venue 2, 2nd floor "Hakone West"

Gastric cancer after eradication

Chair : Yoshio Yamaoka (Oita University)

Hwoon-Yong Jung (Asan Medical Center, University of Ulsan College of Medicine)

JK-S1-1 *Helicobacter pylori*'s base-excision restriction enzyme in stomach carcinogenesis

Ichizo Kobayashi (Hosei University)

JK-S1-2 Gastric Cancer After *Helicobacter pylori* Eradication: Current Insights into Endoscopic Diagnosis, Risk Stratification, and Biomarkers)

Jae Myung Park (College of Medicine, The Catholic University of Korea)

Japan-Korea Joint Symposium 2

July 4(Sat.)14:10~14:40 Venue 2, 2nd floor "Hakone West"

Hot topics in eradication therapy

Chair : Tadashi Shimoyama (Aomori General Health Examination Center)

Jae Gyu Kim (Chung-Ang University College of Medicine)

JK-S2-1 Personalized primary eradication therapy for *Helicobacter pylori* in clinics, considering resistance assessment using nucleic acid amplification test and drug-drug interactions.

Takahisa Furuta (Furuta Clinic for Internal Medicine)

JK-S2-2 Hot Topics in Eradication Therapy: Antimicrobial Resistance, Individualized Regimens, New Regimens, and P-CAB

Ji Yong Ahn (Asan Medical Center, University of Ulsan College of Medicine)

Japan-Korea Joint Symposium 3

July 4(Sat.)14:40~15:10 Venue 2, 2nd floor "Hakone West"

Gastric microbiota (including NHPH) and related diseases

Chair : Mitsushige Sugimoto (Oita University)

Yong Chan Lee (Yonsei University College of Medicine)

JK-S3-1 Giant Autophagy-Related Inclusions in Parietal Cells Are Characteristic of Non-*Helicobacter pylori* *Helicobacter* Infection

Masahiko Nakamura (Tokai University)

JK-S3-2 Gastric microbiota (including NHPH) and related diseases

Cheol Min Shin (Seoul National University College of Medicine)

Presentations by YIA

July 4(Sat.)15:20~16:40 Venue 2, 2nd floor "Hakone West"

Chair : Masumi Okuda (Hyogo Medical College)

Byung-Wook Kim (Catholic University of Korea)

- YIA-1** Endoscopic risk stratification for the patients after *Helicobacter pylori* eradication without the history of gastric cancer
Xinhan Zhang (Hokkaido University Hospital)
- YIA-2** Serum Pepsinogen and Kyoto Classification Reflect Distinct Dimensions of Gastric Mucosal Changes: A Histology-Based Comparative Study
Yuri Kim (Keimyung University School of Medicine)
- YIA-3** Establishment of screening of *H. pylori* infection in junior high school students using urinary antibody and urea breath test in Hirosaki City.
Misa Ozaki (Hokkaido University Hospital)
- YIA-4** Efficacy and Safety of 14-day Fexuprazan-based Triple Therapy for First-line Treatment of *Helicobacter pylori*
So Young Byun (Asan Medical Center, University of Ulsan College of Medicine)
- YIA-5** Real-World Outcomes of *Helicobacter pylori* Eradication Therapy in Patients with Penicillin Allergy: A Retrospective Study
Saki Ubukata (Keio University)
- YIA-6** Clarithromycin and Amoxicillin Susceptibility-Guided Triple Therapy Achieves Consistently High *Helicobacter pylori* Eradication Rates Regardless of Treatment Duration
Hoyoung Wang (Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea)
- YIA-7** Effects of the *Helicobacter pylori* virulence factor Lipoprotein 20 on host response
Takuma Oto (International University of Health and Welfare Graduate School)
- YIA-8** Development of a novel gastric juice-based PCR diagnostic kit for *Helicobacter pylori* infection
Ji Hoon Yoon (Yonsei University College of Medicine)

Poster session

July 4(Sat.)9:30~16:30 Poster venue, 2nd floor "Foyer"

- JK-P-1** Mechanisms of Tetracycline-Resistance in *Helicobacter pylori* Isolated from Korean Patients
Jae Gyu Kim (Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea)
- JK-P-2** Withdrawn
- JK-P-3** Efficacy and Safety of 14-day Fexuprazan-based Triple Therapy for First-line Treatment of *Helicobacter pylori*
Hwoon-Yong Jung (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea)
- JK-P-4** Efficacy and safety of fexuprazan-based modified high-dose dual therapy for *Helicobacter pylori* eradication
Ji Yong Ahn (Division of Gastroenterology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea)

- JK-P-5 Efficacy of fexuprazan-based concomitant therapy for *Helicobacter pylori*: A prospective study**
Seokin Kang (Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea)
- JK-P-6 Clinical outcomes and changes in body composition following endoscopic submucosal dissection versus total gastrectomy in patients with proximal early gastric cancer**
Ga Hee Kim (Institute of Gastroenterology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea)
- JK-P-7 A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TEGOPRAZAN FOR THE PREVENTION OF PEPTIC ULCER IN PATIENTS ON CONTINUOUS LONG-TERM TREATMENT WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS**
Sang Gyun Kim (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea)
- JK-P-8 The role of paraoxonase 1 in *Helicobacter* induced gastritis**
Sung Soo Kim (Department of Internal Medicine, Uijongbu St. Mary's Hospital, The Catholic University of Korea, South Korea)
- JK-P-9 Efficacy of Modified High-Dose Dual Therapy Versus Empirical and Tailored Triple Therapy**
Jung Mogg Kim (Department of Microbiology, Hanyang University College of Medicine, Seoul, Korea)
- JK-P-10 Cost-Effectiveness of Clarithromycin Resistance-Guided Tailored Therapy versus Empirical Therapy for *Helicobacter pylori* Eradication based on different resistance rates**
Joon Sung Kim (Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea)
- JK-P-11 Long-term Result of Endoscopic Submucosal Dissection of Stomach Cancer: A Single Center Experience**
Jeong Seop Moon (Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea, *Isam Hospital, Busan, South Korea)
- JK-P-12 *Helicobacter pylori* eradication and local recurrence after endoscopic treatment of gastric low-grade dysplasia: a Korean multicenter cohort study**
Hyo-Joon Yang (Division of Gastroenterology, Department of Internal Medicine and Gastrointestinal Cancer Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea)
- JK-P-13 Delayed Recognition of Autoimmune Gastritis in APCA-Positive Patients: A Tertiary Center Experience**
Myung-Hun Lee (Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea)
- JK-P-14 RISK STRATIFICATION SYSTEM FOR ELDERLY PATIENTS WITH EARLY GASTRIC CANCER AFTER NON-CURATIVE ENDOSCOPIC RESECTION IN KOREA: A NATIONWIDE MULTICENTER RETROSPECTIVE STUDY**
Jeong Hoon Lee (Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea)
- JK-P-15 The infection rate of *Helicobacter pylori* and the effect of eradication on reducing gastric cancer in one's thirties: local population-based cohort study**
Seong Woo Jeon (Daegu-Kyungpook Regional Cancer Center, Gastroenterology, Kyungpook National University Chilgok Hospital, Daegu, Korea)

- JK-P-16 Antibody Titer Conversion After *H. pylori* Eradication Predicts Improvement in Endoscopic Atrophic Gastritis**
Su Jin Chung (Seoul National University Hospital Healthcare System Gangnam Center)
- JK-P-17 Optimal range of grey zone for 13C-urea breath test on *Helicobacter pylori* infection diagnosis**
Jun-Won Chung (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Republic of Korea)
- JK-P-18 Phenotype-specific epidemiological trends in eosinophilic gastrointestinal diseases: A 22-Year Tertiary Center Study**
Hye-Kyung Jung (Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea)
- JK-P-19 Clinical Risk Factors of Metachronous Recurrence after Curative ESD for Early Gastric Cancer: Implications for Long-term Surveillance**
Moon Kyung Joo (Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148, Gurodong-ro, Guro-gu, Seoul, Republic of Korea)
- JK-P-20 Tailored Therapy for *H. pylori* Based on Macrolide Exposure versus PCR Test : An Interim Analysis**
Kee Don Choi (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea)
- JK-P-21 Comparison of the Microbiome Diversity in Gastric Cancer Patients and Non-Cancerous Patients**
Hyuk Soon Choi (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea)
- JK-P-22 A base-excising restriction enzyme from *H. pylori* induces gastric cancer-associated mutations**
Fukuyo Masaki (Chiba University, Chiba, Japan)